Neurosurgery
Molecular Features of Glioblastoma Isocitrate Dehydrogenase-Wildtype in Extreme Survival Groups After Supramaximal and Maximal Resection.
Angel Bueno, Antonio Dono, Christian Amezquita-Contreras, Kamand Khalaj, Ankush Chandra, Andres Rodriguez, Pavel S Pichardo-Rojas, Sigmund Hsu, Mark Amsbaugh, Jay-Jiguang Zhu, Angel I Blanco, Roy F Riascos, Leomar Y Ballester, Nitin Tandon, Yoshua Esquenazi
Published: 202610.1227/neu.0000000000003929
Abstract
BACKGROUND AND OBJECTIVES: Glioblastoma (GBM) isocitrate dehydrogenase-wildtype remains a devastating brain tumor with a poor prognosis despite optimal treatment. Even after supramaximal or complete contrast-enhancing (CE) resection, patient outcomes…
Preview only. Read the full abstract at the source